The FDA approved reformulated ranitidine tablets, marking the acid-reducing drug’s return to the U.S. market after a five-year absence.
The updated formulation underwent safety testing and manufacturing revisions to address concerns about the formation of N-nitrosodimethylamine (NDMA), an impurity linked to cancer risk, during the drug’s shelf life, according to a Nov. 24 news release from the FDA.
Approved ranitidine products will carry revised labeling with storage and handling instructions. Patients are now instructed to keep tablets in the original container with a desiccant, use them within 90 days of opening and open only one bottle at a time if multiple are dispensed.
Ranitidine is a histamine-2 receptor antagonist indicated for gastroesophageal reflux disease, peptic ulcers and Zollinger-Ellison syndrome. The reformulated product maintains the same therapeutic effectiveness as earlier versions, the FDA said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
